MGTX vs PTGX: fair value comparison
MeiraGTx Holdings plc and Protagonist Therapeutics, Inc. · Updated 2026-10-19
MGTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. PTGX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PTGX currently ranks higher by quality score.
| MGTX | PTGX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $9.28 | $128.75 |
| 12-month range | $6.99–$14.97 | $73.98–$158.62 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #90 of 301 Healthcare | #88 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: MGTX fair value analysis · PTGX fair value analysis